Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy

Inclusion Criteria

Concurrent Medication:

Allowed:

• Maintenance therapy for opportunistic infections.

Patients must have:

• HIV infection.
• Kaposi's sarcoma that has relapsed or progressed.
• Mucocutaneous lesions (15 or more) and/or symptomatic mucosal lesions and/or visceral Kaposi's sarcoma (symptomatic lymphedema qualifies patients in the absence of these three conditions).
• NO active acute opportunistic infections requiring treatment with myelosuppressive antibiotics (maintenance for OIs is permitted).
• Consent of parent or guardian if less than 18 years of age.

NOTE:

• This study is approved for prisoner participation.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Other active malignancies except basal cell carcinoma of the skin, or carcinoma in situ of the cervix.
• Grade 3 or worse peripheral neuropathy.
• Altered mental status that would prevent informed consent or prevent study compliance.

Patients with the following prior condition are excluded:

Neuropsychiatric history.

Prior Medication:

Excluded:

• Prior etoposide.
• Any other anti-KS drugs within 14 days prior to study entry.
• Any investigational drug other than antiretrovirals within 14 days prior to study entry.
• Any prior investigational agent, if given as the ONLY prior treatment for KS.

Prior Treatment:

Excluded:

• Radiation therapy within 7 days prior to study entry.

Continued alcohol consumption or continued intravenous drug use that would impair ability to comply with study requirements.